CEO Jared Bauer applies a core lesson from his time at Apple to biotech: focus on the user experience, not the technical specifications. Instead of highlighting 'how fast the RAM is,' Apple focuses on what it enables, a principle he uses to guide product development.
Related Insights
The apocryphal Henry Ford quote is often used to dismiss customer research. Yet highly innovative companies like Apple invest millions studying customers to find deep-seated problems, not to ask for solutions. The real lesson is to research customer pains to inform visionary products.
A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.
While scientific acumen is valuable, the most critical trait for a biotech CEO is perseverance. The role involves weathering constant challenges where everyone—the board, investors, employees—can seem to be against you. An unwavering focus on the patient mission is essential to push through.
Successful MedTech innovation starts by identifying a pressing, real-world clinical problem and then developing a solution. This 'problem-first' approach is more effective than creating a technology and searching for an application, a common pitfall for founders with academic backgrounds.
Successful biotech leadership requires a clear decision-making hierarchy. Dr. Bahija Jallal advocates for a framework where patient welfare is paramount, followed by scientific rigor. Financial success is treated as a byproduct of excelling in the first two areas, not the primary goal.
VC Claire Smith defines "Tech Bio" as a "tech-first" approach, where a novel hardware or software platform is the core innovation, which is then applied to solve biological problems. This contrasts with traditional biotech, which starts with a biological insight (like a target) and then uses a toolbox of existing technologies.
A crucial piece of advice for biotech founders is to interact with patients as early as possible. This 'patient first' approach helps uncover unmet needs in their treatment journey, providing a more powerful and differentiated perspective than focusing solely on the scientific or commercial landscape.
The fundamental purpose of any biotech company is to leverage a novel technology or insight that increases the probability of clinical trial success. This reframes the mission away from just "cool science" to having a core thesis for beating the industry's dismal odds of getting a drug to market.
While AI wearables like Humane and Rabbit failed, Limitless thrives by starting with a core human problem—flawed memory—and working backward to the technology. Competitors started with a 'wouldn't it be cool if' tech-first approach, which often fails to find a market.
Gene therapy companies, which are inherently technology-heavy, risk becoming too focused on their platform. The ultimate stakeholder is the patient, who is indifferent to whether a cure comes from gene editing, a small molecule, or an antibody. The key is solving the disease, not forcing a specific technological solution onto every problem.
